Direct Oral Anticoagulant Use: A Practical Guide to Common …
2020年6月15日 · Direct oral anticoagulants (DOACs)—dabigatran (Pradaxa), rivaroxaban (Xarelto), apixaban (Eliquis), edoxaban (Savaysa), and betrixaban (Bevyxxa) are anticoagulation pharmacotherapy used for the prevention of thrombosis in several cardiovascular contexts. 1 DOACs are categorized into 2 main classes: oral direct factor Xa inhibitors (ie ...
Two in vitro studies demonstrate that dabigatran can successfully be adsorbed by activated charcoal in the stomach fluid as well as the plasma Recommendation: Give activated charcoal 1-2 hours post-overdose before intestinal absorption occurs
Dosing and Administration of Pradaxa® (dabigatran etexilate)
optimal timing between the administration of PRADAXA and neuraxial procedures is not known. Monitor patients frequently for signs and symptoms of neurological impairment. If neurological compromise is noted, urgent treatment is necessary. Consider the benefits and risks before neuraxial intervention in patients who are or will be anticoagulated.
Direct oral anticoagulant monitoring: what laboratory tests …
2019年12月6日 · Direct oral anticoagulants (DOACs) are increasingly used in the treatment and prophylaxis of thromboembolism because of several advantages over vitamin K antagonists, including no need for laboratory monitoring.
Testing and monitoring direct oral anticoagulants
2018年11月8日 · Determination of dabigatran, rivaroxaban and apixaban by ultra-performance liquid chromatography - tandem mass spectrometry (UPLC-MS/MS) and coagulation assays for therapy monitoring of novel direct oral anticoagulants
Clinical Monitoring of Direct Acting Oral Anticoagulants
2017年3月21日 · Important monitoring limitations of DOACs include the inability to assess anticoagulant activity, the need to assess renal function before initiation and with ongoing therapy, and the required strict adherence to ensure complete efficacy due to their short duration of action.
Monitoring anticoagulant therapy with new oral agents - PMC
The present review aims to summarize the current knowledge regarding the clinical question of how and when to monitor patients with new anticoagulant oral agents. Keywords: Anticoagulant agents, Apixaban, Dabigatran, Drug monitoring, Rivaroxaban
Laboratory and Clinical Monitoring of Direct Acting Oral …
2016年12月16日 · Noncoagulation laboratory monitoring should include serum creatinine, liver function tests, and complete blood counts. Clinical monitoring of the DOAC-treated patient should include routine assessment of adherence, bleeding risks, and drug interactions.
Noncoagulation laboratory monitoring should include serum creatinine, liver function tests, and complete blood counts. Clinical monitoring of the DOAC-treated patient should include routine assessment of adherence, bleeding risks, and drug interactions.
Dabigatran is a new anticoagulant for reducing the risk of stroke in patients with atrial fibrillation. Dabigatran is a direct thrombin inhibitor, similar to warfarin, without requiring INR monitoring and dose adjustments. Choosing between warfarin and dabigatran can depend on patient considerations and preferences.